News | January 24, 2026
Rising demand for obesity drugs hits employer healthcare budgets, says Howden Report
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
Subscribe To Our Newsletter & Stay Updated
